These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38640325)
1. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer. Meng M; Liu X; Liang X; Chen X; Li Y Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325 [TBL] [Abstract][Full Text] [Related]
2. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis. Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective. Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237 [TBL] [Abstract][Full Text] [Related]
6. First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis. Liu Q; Luo X; Yi L; Zeng X; Tan C Front Oncol; 2021; 11():699781. PubMed ID: 34268124 [TBL] [Abstract][Full Text] [Related]
7. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. Paz-Ares L; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Musso E; Havel L; Bondarenko I; Losonczy G; Conev N; Mann H; Dalvi TB; Jiang H; Goldman JW ESMO Open; 2022 Apr; 7(2):100408. PubMed ID: 35279527 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer. Liang X; Chen X; Li H; Li Y Front Public Health; 2023; 11():1156427. PubMed ID: 37727602 [TBL] [Abstract][Full Text] [Related]
9. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L; Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097 [TBL] [Abstract][Full Text] [Related]
10. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495 [TBL] [Abstract][Full Text] [Related]
12. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Zhu Y; Liu K; Qin Q; Zhu H Front Immunol; 2022; 13():1044678. PubMed ID: 36685541 [TBL] [Abstract][Full Text] [Related]
13. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW; Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Liu G; Kang S Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Goldman JW; Garassino MC; Chen Y; Özgüroğlu M; Dvorkin M; Trukhin D; Statsenko G; Hotta K; Ji JH; Hochmair MJ; Voitko O; Havel L; Poltoratskiy A; Losonczy G; Reinmuth N; Patel N; Laud PJ; Shire N; Jiang H; Paz-Ares L Lung Cancer; 2020 Nov; 149():46-52. PubMed ID: 32961445 [TBL] [Abstract][Full Text] [Related]
16. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer. Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review. Wang T; Li Y; Zheng X BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540 [TBL] [Abstract][Full Text] [Related]
18. First-Line Durvalumab Plus Platinum-Etoposide Zhang L; Hang Y; Liu M; Li N; Cai H Front Oncol; 2020; 10():602185. PubMed ID: 33344252 [TBL] [Abstract][Full Text] [Related]
19. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. Su D; Wu B; Shi L JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]